<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Soc. Trans</journal-id><journal-id journal-id-type="hwp">ppbiost</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26517881</article-id><article-id pub-id-type="pmc">4613458</article-id><article-id pub-id-type="publisher-id">BST20150126</article-id><article-id pub-id-type="doi">10.1042/BST20150126</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biochemical Society Awards</subject><subj-group><subject>The Centenary Award</subject></subj-group></subj-group><subj-group subj-group-type="overline"><subject>The Centenary Award</subject></subj-group><subj-group subj-group-type="Primary"><subject>S5</subject></subj-group><subj-group subj-group-type="Secondary"><subject>S7</subject></subj-group></article-categories><title-group><article-title>Signalling to eIF4E in cancer</article-title><alt-title alt-title-type="right-running-head">The Centenary Award</alt-title><alt-title alt-title-type="left-running-head">Biochemical Society Transactions (2015) Volume 43, part 5</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Siddiqui</surname><given-names>Nadeem</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="corresp" rid="COR1"><sup>1</sup></xref></contrib><aff id="A1"><label>*</label>Department of Biochemistry and Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Montreal, Quebec, Canada H3A 1A3</aff></contrib-group><author-notes><corresp id="COR1"><bold><sup>1</sup>To whom correspondence should be addressed (email</bold><email>nahum.sonenberg@mcgill.ca</email><bold>)</bold>.</corresp><fn><p><bold>Award lecture presented at the Biochemical Society Centenary Celebration. Held at the Royal Society, London, U.K., 15&#x02013;16 December 2011.</bold></p></fn></author-notes><pub-date pub-type="epub"><day>9</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>10</month><year>2015</year></pub-date><volume>43</volume><issue>5</issue><issue-id pub-id-type="display">5</issue-id><fpage>763</fpage><lpage>772</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Authors; published by Portland Press Limited</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="bst0430763.pdf"/><abstract><p>Translational control plays a critical role in the regulation of gene expression in eukaryotes and affects many essential cellular processes, including proliferation, apoptosis and differentiation. Under most circumstances, translational control occurs at the initiation step at which the ribosome is recruited to the mRNA. The eukaryotic translation initiation factor 4E (eIF4E), as part of the eIF4F complex, interacts first with the mRNA and facilitates the recruitment of the 40S ribosomal subunit. The activity of eIF4E is regulated at many levels, most profoundly by two major signalling pathways: PI3K (phosphoinositide 3-kinase)/Akt (also known and Protein Kinase B, PKB)/mTOR (mechanistic/mammalian target of rapamycin) and Ras (rat sarcoma)/MAPK (mitogen-activated protein kinase)/Mnk (MAPK-interacting kinases). mTOR directly phosphorylates the 4E-BPs (eIF4E-binding proteins), which are inhibitors of eIF4E, to relieve translational suppression, whereas Mnk phosphorylates eIF4E to stimulate translation. Hyperactivation of these pathways occurs in the majority of cancers, which results in increased eIF4E activity. Thus, translational control via eIF4E acts as a convergence point for hyperactive signalling pathways to promote tumorigenesis. Consequently, recent works have aimed to target these pathways and ultimately the translational machinery for cancer therapy.</p></abstract><kwd-group kwd-group-type="kwd"><kwd>cancer therapy</kwd><kwd>eukaryotic translation initiation factor 4E (eIF4E)</kwd><kwd>eukaryotic translation initiation factor 4E-binding proteins (4E-BPs)</kwd><kwd>mitogen-activated protein kinase-interacting kinase 1/2 (Mnk1/2)</kwd><kwd>mechanistic/mammalian target of rapamycin (mTOR)</kwd><kwd>phospho-4E</kwd></kwd-group><counts><fig-count count="3"/><ref-count count="116"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>mRNA translation is divided into three steps: initiation, elongation and termination [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Initiation is the rate-limiting step of translation and is subject to extensive regulation. A large body of evidence shows that translational control occurs predominately at the initiation step [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. All nuclear transcribed mRNAs contain the cap structure or &#x02018;5&#x02032;-cap&#x02019;, m7GpppN (where m is a methyl group and N is any nucleotide), which is added very early at the transcription elongation step [<xref rid="B6" ref-type="bibr">6</xref>]. Translation initiation in eukaryotes commences with the binding of the eukaryotic translation initiation factor 4F (eIF4F) complex to the 5&#x02032;-cap (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref rid="B6" ref-type="bibr">6</xref>]. eIF4F consists of the cap-binding subunit, eIF4E, the RNA helicase eIF4A and the scaffolding protein eIF4G [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. It is thought that eIF4A unwinds the secondary structure present in the 5&#x02032;-UTR of the mRNA to promote the binding of the ribosome and its scanning of the 5&#x02032;-UTR [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. Several other helicases, such as Ded1 and DHX29 (DEAH box polypeptide 29), are also involved in this process [<xref rid="B8" ref-type="bibr">8</xref>]. eIF4G interacts directly with eIF4E, eIF4A, eIF3 and the poly (A)-binding protein (PABP) [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. The interaction of eIF4G with the multi-component initiation factor eIF3 is required in mammals for the recruitment of the 43S pre-initiation complex (which consists of the 40S ribosomal subunit and associated initiation factors), via the direct binding of eIF3 to the 40S subunit [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. Following assembly at the cap structure, the 43S pre-initiation complex traverses the mRNA 5&#x02032;UTR in a 5&#x02032; to 3&#x02032; direction, until it encounters the initiation codon (usually AUG, but in rare cases a near-cognate AUG), where it stops and the 60S large ribosomal subunit joins to form the 80S ribosomal complex, which is followed by the translation elongation step [<xref rid="B9" ref-type="bibr">9</xref>]. The eIF4G interaction with PABP brings about the circularization of the mRNA, which is thought to facilitate the shunting of ribosomes from the termination codon to the mRNA 5&#x02032;-cap to stimulate translation [<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>Model of cap dependent translation initiation</title><p>eIF4F binds to the m<sup>7</sup>G cap structure via the cap-binding protein eIF4E. eIF4G is a scaffold protein which also binds to the RNA helicase eIF4A and eIF3, which in turn recruits the 43S pre-initiation complex (PIC). The PIC consists of the 40S ribosomal subunit, eIF2-GTP-Met-tRNAi and several other initiation factors, which are indicated. eIF4A melts the secondary structure in the 5&#x02032;-UTR and the PIC scans the mRNA until it encounters the AUG start codon where the 60S subunit joins, followed by peptide chain synthesis. eIF4G also binds to PABP which brings about the circularization of the mRNA allowing for efficient ribosome recycling.</p></caption><graphic xlink:href="bst0430763fig1"/></fig><p>With the exception of mRNAs that translate via an internal ribosome entry site (IRES), the vast majority of eukaryotic mRNAs are translated in a cap-dependent manner [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. Although eIF4E is necessary for cap-dependent translation, its requirement varies dramatically among mRNAs, as it preferentially stimulates the translation of a subset of mRNAs which are referred to as &#x02018;eIF4E-sensitive&#x02019; [<xref rid="B12" ref-type="bibr">12</xref>]. These mRNAs mostly include those encoding proliferation and survival-promoting proteins such as cyclin D1 and D3, c-Myc, MDM2 (mouse double minute 2), VEGF (vascular endothelial growth factor), survivin and Bcl-2 (B-cell lymphoma 2) [<xref rid="B13" ref-type="bibr">13</xref>]. Considerable research efforts have been dedicated to the understanding of the mechanism that explains the preference for eIF4E-sensitive mRNAs. In general, mRNAs containing long G/C-rich 5&#x02032;-UTRs, with the potential of forming stable secondary structures are feebly translated [<xref rid="B14" ref-type="bibr">14</xref>]. Reducing secondary structure by denaturing the mRNA enhances translation [<xref rid="B15" ref-type="bibr">15</xref>], whereas inserting sequences in the mRNA 5&#x02032;-UTR that can form secondary structure impairs translation [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>]. Strikingly, mRNAs with increased secondary structure are highly dependent on the cap structure for efficient translation [<xref rid="B16" ref-type="bibr">16</xref>]. Consistent with these studies, mRNAs with extensive secondary-structure in their 5&#x02032;-UTRs are exceedingly dependent on eIF4E and eIF4A activity [<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>]. These observations can be mechanistically explained by recent findings showing that eIF4E exhibits a novel activity [<xref rid="B23" ref-type="bibr">23</xref>]. The eIF4E-binding region within eIF4G can inhibit eIF4A helicase activity when not bound to eIF4E. This inhibition is alleviated upon eIF4E binding to eIF4G. Thus, in addition to its canonical function as the 5&#x02019;-cap-binding protein, eIF4E indirectly stimulates eIF4A helicase activity [<xref rid="B23" ref-type="bibr">23</xref>]. Recent reports have identified other motifs in mammalian mRNA 5&#x02032;-UTRs that confer stimulation via eIF4E. These include terminal oligo pyrimidine (TOP) sequences at the mRNA extreme 5&#x02032;-end and TOP-like mRNAs, which contain pyrimidine-rich sequences distal to the mRNA 5&#x02032;end [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>]; see other reports with additional conclusions [<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. The mechanisms by which eIF4E preferentially up-regulates the translation of TOP mRNAs are unknown.</p><p>eIF4E amounts and activity are regulated by multiple mechanisms. These include: (1) amplification of the gene encoding eIF4E; (2) transcriptional activation, particularly by c-Myc; (3) control of eIF4E activity by eIF4E-binding proteins (4E-BPs) and (4) post-translational modifications such as phosphorylation [<xref rid="B12" ref-type="bibr">12</xref>]. There are three 4E-BP homologues in mammals: 4E-BP1, 2 and 3 [<xref rid="B7" ref-type="bibr">7</xref>]. 4E-BPs and eIF4G share a common binding site for eIF4E [<xref rid="B28" ref-type="bibr">28</xref>]; thus, the interaction of 4E-BPs with eIF4E precludes the binding of eIF4E to eIF4G, causing impaired assembly of the eIF4F complex [<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>). 4E-BPs are phosphoproteins, whose binding to eIF4E is determined by their phosphorylation status. The dephosphorylated forms of 4E-BPs bind avidly to eIF4E and therefore act as translational suppressors.</p><fig id="F2" position="float"><label>Figure 2</label><caption><title>Signal transduction pathways converging on eIF4E</title><p>The PI3K pathway is activated in response to many extracellular stimuli resulting in the activation of the downstream serine/threonine kinase, mTOR. mTOR is a multi-domain protein which associates with several binding partners to form two different complexes mTORC1 and mTORC2. mTORC1 phosphorylates the translation repressors 4E-BPs, which then dissociate from eIF4E, allowing eIF4F formation and thus promoting translation. Mitogenic and stress signals activate components of the MAPK pathway including the ERK and p38 MAP kinase. Both converge to activate Mnk1/2, which bind to eIF4G and phosphorylate eIF4E at Ser<sup>209</sup>. Both pathways are hyperactivated in the majority of human malignancies. Drugs targeting, these signalling pathways and translation initiation factors are shown in red.</p></caption><graphic xlink:href="bst0430763fig2"/></fig></sec><sec><title>The mTOR pathway regulates eIF4E</title><p>The mechanistic/mammalian target of rapamycin (mTOR) is a highly evolutionarily conserved serine/threonine kinase that controls a staggering number of key cellular processes including protein synthesis, cell growth and proliferation, lipid metabolism, mitochondrial function, autophagy and cytoskeleton organization [<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>]. mTOR forms two separate complexes: mTOR complex 1 and 2 (mTORC1 and mTORC2) [<xref rid="B32" ref-type="bibr">32</xref>] [<xref rid="B34" ref-type="bibr">34</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>). Both mTOR complexes share the protein subunit LST8 (lethal with sec13 protein 8)/G&#x003b2;L (G-protein beta subunit like) [<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. mTORC1 contains the subunit Raptor that functions as an adaptor for the substrates of mTORC1, such as 4E-BPs, S6 kinases, PRAS40 (proline rich Akt substrate of 40 kDa) and Deptor [<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B36" ref-type="bibr">36</xref>]. mTORC2 contains the subunits Rictor, Sin1 (stress activated protein-kinase interacting protein) and Protor [<xref rid="B32" ref-type="bibr">32</xref>]. mTORC1 integrates a large number of inputs including extracellular stimuli signals such as growth factors, hormones and stress as well as intracellular cues, such as energy status, amino acid amounts and oxygen levels [<xref rid="B37" ref-type="bibr">37</xref>]. mTORC1 is activated via ordered serine/threonine phosphorylation and GTPase events, which constitute the PI3K (phosphoinositide 3-kinase)/Akt/mTOR signalling pathway. PI3K is a lipid kinase that phosphorylates phosphatidyl inositol 3,4 (PIP<sub>2</sub>) to generate phosphatidyl inositol 3,4,5 (PIP<sub>3</sub>), which activates the kinase Akt (also known as protein kinase B) [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B38" ref-type="bibr">38</xref>]. The action of PI3K is antagonized by PTEN (phosphatase and tensin homologue on chromosome 10) a PIP<sub>3</sub> phosphatase [<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>]. PIP<sub>3</sub> binds to the pleckstrin homology (PH) domain of Akt to promote the translocation of Akt to the plasma membrane [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>], where it is phosphorylated and activated by several kinases including mTORC2 [<xref rid="B44" ref-type="bibr">44</xref>]. Among its numerous targets, phosphorylation of tuberous sclerosis complex 2 (TSC2; a subunit of the tuberous sclerosis complex) by Akt stimulates mTORC1 activity [<xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>]. Arguably, the best-studied and understood function of mTORC1 is its role in translation control. mTORC1 phosphorylates (inactivates) the 4E-BPs, leading to their dissociation from eIF4E which allows eIF4F formation and translation progression [<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>). In our laboratory, we investigated the role of mTOR in promoting the translation of the &#x02018;eIF4E-sensitive&#x02019; subset of mRNAs via the eIF4F complex [<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>].</p></sec><sec><title>Phosphorylation of eIF4E and cancer</title><p>eIF4E was suggested to act as an oncogene because it malignantly transformed NIH 3T3 murine fibroblasts [<xref rid="B52" ref-type="bibr">52</xref>] and subsequently rat primary embryo fibroblasts, in combination with c-Myc or adenovirus E1A [<xref rid="B53" ref-type="bibr">53</xref>] and human mammary cells [<xref rid="B54" ref-type="bibr">54</xref>]. It is remarkable that a relatively modest level of overexpression (&#x0223c;2.5-fold) of eIF4E in NIH 3T3 was sufficient to cause transformation [<xref rid="B55" ref-type="bibr">55</xref>]. This is highly significant, because in human cancers the magnitude of eIF4E increase is in this range [<xref rid="B56" ref-type="bibr">56</xref>]. Consistent with these results, depletion of eIF4E significantly reduced Ras-mediated tumorigenesis [<xref rid="B57" ref-type="bibr">57</xref>]. The conclusions from the <italic>in&#x000a0;vitro</italic> experiments were bolstered by subsequent <italic>in&#x000a0;vivo</italic> work in mice, which showed that overexpression of eIF4E augmented E&#x003bc;-Myc-driven lymphomas [<xref rid="B58" ref-type="bibr">58</xref>] and engendered cancers in a multitude of organs, when expressed from the &#x003b2;-actin promoter [<xref rid="B59" ref-type="bibr">59</xref>]. eIF4E activity is also regulated via the MAPK (mitogen-activated protein kinase) pathway through direct phosphorylation by the MAPK-interacting kinases (Mnk1 and Mnk2) at a single residue, Ser<sup>209</sup> [<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>]. Phosphorylation of eIF4E plays an important role in cancer development and progression [<xref rid="B62" ref-type="bibr">62</xref>&#x02013;<xref rid="B65" ref-type="bibr">65</xref>]. Ectopic expression of the eIF4E<sup>S209A</sup> mutant protein failed to cause neoplastic transformation in NIH 3T3 cells and in the E&#x003bc;-Myc lymphoma mouse model [<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref>]. Engineered knockin mice, in which the wild-type allele of eIF4E was replaced by the eIF4E<sup>S209A</sup> allele, were crossed with mice in which PTEN was deleted in the prostate. This deletion causes early onset of prostate intraepithelial neoplasia (PIN) and invasive carcinoma [<xref rid="B66" ref-type="bibr">66</xref>]. However, strikingly, the eIF4E<sup>S209A</sup> mutant mice were resistant to PIN and invasive carcinoma [<xref rid="B64" ref-type="bibr">64</xref>]. These results are highly relevant to human prostate cancer, inasmuch as eIF4E amounts and phosphorylation are gradually elevated in the progression of prostate cancer from PIN through hormone-sensitive and hormone-resistant forms [<xref rid="B64" ref-type="bibr">64</xref>]. In more recent studies, the mutant eIF4E<sup>S209A</sup> mouse was also shown to be resistant to polyoma middle-T driven mammary tumours [<xref rid="B65" ref-type="bibr">65</xref>]. Availability and phosphorylation of eIF4E promote metastasis in mice [<xref rid="B67" ref-type="bibr">67</xref>,<xref rid="B68" ref-type="bibr">68</xref>]. Translation of a subset of mRNAs, encoding several pro-metastatic proteins, such as MMP-3 (matrix metalloproteinase-3) and MMP-9, was reduced in the mutant eIF4E<sup>S209A</sup> mouse. MMPs cleave constituents of the extracellular matrix and promote migration and invasion [<xref rid="B69" ref-type="bibr">69</xref>]. eIF4E phosphorylation stimulated the translation of <italic>Mmp3</italic> and <italic>Snail</italic> mRNAs whose proteins promote invasion and epithelial-to-mesenchymal transition (EMT), which is required for metastasis [<xref rid="B64" ref-type="bibr">64</xref>]. Indeed, tumour growth factor &#x003b2; (TGF&#x003b2;), which is an established inducer of EMT [<xref rid="B70" ref-type="bibr">70</xref>], promotes the phosphorylation of eIF4E via activation of ERK (extracellular signal regulated kinase) and p38 MAPK, which phosphorylate Mnk [<xref rid="B71" ref-type="bibr">71</xref>]. Strikingly, the phosphorylation of eIF4E by MNK1 is required for TGF&#x003b2;-induced EMT [<xref rid="B65" ref-type="bibr">65</xref>].</p></sec><sec><title>Strategies for targeting eIF4E in cancer therapy</title><p>In light of the idea that eIF4E is a convergence point for the major cancer related signalling pathways [<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>) and that eIF4E is activated or overexpressed in a large number of tumours, there has been considerable effort to target eIF4E directly or indirectly for cancer therapy. eIF4E activity in cancer can be targeted indirectly by inhibitors of the PI3K/Akt/mTOR pathway, which cause the dephosphorylation of 4E-BPs and inhibition of eIF4E. Some of these compounds, prominently rapamycin derivatives (rapalogues) are in use in the clinic for certain cancers, but many more are in clinical trials, particularly PI3K inhibitors and active-site mTOR inhibitors (asTORi); the latter inhibiting both mTORC1 and mTORC2 [<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B75" ref-type="bibr">75</xref>]. A highly pertinent question is whether eIF4E is a pivotal target that mediates the therapeutic activity of these inhibitors in cancer. Some affirmative answers to this question were obtained recently showing that cells in culture, which develop resistance to these drugs exhibit amplified eIF4E. Cells that became resistant to NVP-BEZ235, which is a dual PI3K/mTOR inhibitor, exhibited amplified c-Myc and eIF4E genes [<xref rid="B76" ref-type="bibr">76</xref>] and cells which acquired resistance to AZD8055, an asTORi, had amplified eIF4E [<xref rid="B77" ref-type="bibr">77</xref>]. These results support earlier findings from our laboratory that the ratio of eIF4E/4E-BP is a prime predictor of the efficacy of asTORi in reducing tumour growth in mice [<xref rid="B78" ref-type="bibr">78</xref>]. Moreover, asTORi inhibit cell proliferation, but not cell growth via inhibition of 4E-BP phosphorylation and subsequent suppression of translation of &#x02018;eIF4E-sensitive&#x02019; mRNAs [<xref rid="B79" ref-type="bibr">79</xref>].</p><p>One of the first attempts to target eIF4E directly was undertaken by Graff et al. [<xref rid="B80" ref-type="bibr">80</xref>] by developing an anti-sense oligonucleotide (ASO) against eIF4E, which preferentially inhibited the translation of eIF4E-sensitive mRNAs encoding proteins, such as VEGF, cyclin D1, survivin, c-Myc, and Bcl-2, in cultured cells. Most striking was the observation that intravenous administration of ASO selectively reduced eIF4E expression in human tumour xenografts and dramatically suppressed tumour growth. eIF4E ASO reduced eIF4E levels in the mouse (80% in the liver), but importantly, had no effect on body weight, organ weight or liver transaminase levels [<xref rid="B80" ref-type="bibr">80</xref>]. The puzzling question as to why a dramatic reduction in eIF4E did not significantly impair translation but rather caused only minimal deleterious effects in the mouse is most probably explained by results obtained from cells in culture in which shRNA was used to deplete eIF4E [<xref rid="B81" ref-type="bibr">81</xref>]. When eIF4E is dramatically reduced, the non-phosphorylated 4E-BPs, which no longer have a binding partner, undergo ubiquitination and subsequent degradation [<xref rid="B81" ref-type="bibr">81</xref>]. Thus, depletion of eIF4E also causes a reduction in the amounts of its inhibitory 4E-BPs and therefore, the potential deleterious effects of eIF4E depletion are significantly ameliorated.</p><p>As described above, phosphorylation of eIF4E plays an important role in cancer progression. Thus, another strategy to diminish eIF4E activity has been to develop drug-candidate compounds that target Mnks to prevent eIF4E phosphorylation [<xref rid="B82" ref-type="bibr">82</xref>]. These include CGP57380 [<xref rid="B83" ref-type="bibr">83</xref>], cercosporamide [<xref rid="B84" ref-type="bibr">84</xref>] and 5-(2-(phenylamino) pyrimidin-4-yl)thiazol-2(3H)-one derivatives [<xref rid="B85" ref-type="bibr">85</xref>]. As double &#x02018;knockout&#x02019; Mnk1/2 mice develop normally and appear healthy [<xref rid="B86" ref-type="bibr">86</xref>], compounds that acutely inhibit Mnk activity are highly attractive candidates to treat cancer.</p><p>Another class of promising inhibitors comprises compounds that prevent eIF4E&#x02013;eIF4G interactions [<xref rid="B87" ref-type="bibr">87</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>). These compounds disrupt the formation of the eIF4F complex, and therefore impair translation of eIF4E-sensitive mRNAs. The archetype of this family of compounds, 4EGI-1, suppressed the growth and induced apoptosis of multiple myeloma and lung cancer cells <italic>in&#x000a0;vitro</italic> and inhibited myeloma and breast cancer xenografts without apparent toxicity <italic>in&#x000a0;vivo</italic> [<xref rid="B88" ref-type="bibr">88</xref>&#x02013;<xref rid="B92" ref-type="bibr">92</xref>]. Accordingly, current efforts are focused on developing more potent analogues of 4EGI [<xref rid="B93" ref-type="bibr">93</xref>&#x02013;<xref rid="B95" ref-type="bibr">95</xref>]. Mechanistically, 4EGI-1 binds to a region of eIF4E that is distant from the eIF4E-eIF4G interface and induces an allosteric inhibition of the interaction between the two-subunits [<xref rid="B87" ref-type="bibr">87</xref>]. In addition to preventing eIF4G&#x02013;eIF4E interaction, 4EGI-1 also stabilizes the 4E-BP binding to eIF4E, which exacerbates the translation inhibition of eIF4E-sensitve mRNA [<xref rid="B87" ref-type="bibr">87</xref>]. This observation was initially surprising and suggested that eIF4G and 4E-BPs may have some non-overlapping interaction sites with eIF4E. Indeed, recent structural studies have shown that 4E-BP2 contains a non-canonical motif (conserved in all 4E-BPs), which contacts a region of eIF4E that is not used by eIF4G [<xref rid="B96" ref-type="bibr">96</xref>,<xref rid="B97" ref-type="bibr">97</xref>]. Further structural characterization of eIF4E complexes revealed unique binding elements in different eIF4E binding partners that could be fused into a chimeric &#x02018;4E-BP-like&#x02019; mimic and dampen translational activity [<xref rid="B98" ref-type="bibr">98</xref>]. NMR studies using the full-length 4E-BP revealed that phosphorylation of 4E-BP results in a transition from a binding-competent disordered state to a folded state that cannot bind to eIF4E [<xref rid="B99" ref-type="bibr">99</xref>]. The latter findings raise for the first time the intriguing possibility of targeting a regulator of eIF4E. It is proposed that small molecules could be designed to alter the stability of 4E-BPs and thus alter its affinity for eIF4E [<xref rid="B99" ref-type="bibr">99</xref>]. Taken together, these detailed structural studies will aid in the rational design of more potent treatments such as 4EGI-like compounds, 4E-BPs mimics or small molecules that stabilize 4E-BP-eIF4E interactions.</p><p>As eIF4E's role in tumorigenesis depends on its ability to bind the 5&#x02032;-cap, a key strategy has focused on developing bioavailable 5&#x02032;-cap analogues which directly target eIF4E [<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B100" ref-type="bibr">100</xref>]. For instance, numerous atomic structures of eIF4E have been studied in great detail, with and without different 5&#x02032;-cap structures [<xref rid="B87" ref-type="bibr">87</xref>], which have aided in the design of 5&#x02032;-cap-mimetics such as 4Ei-1 [<xref rid="B101" ref-type="bibr">101</xref>]. 4Ei-1 inhibited cap-dependent translation and exhibited anti-neoplastic activities with minimal toxic effects [<xref rid="B101" ref-type="bibr">101</xref>&#x02013;<xref rid="B103" ref-type="bibr">103</xref>]. High throughput screening efforts for more effective 5&#x02032;-cap mimetics are ongoing [<xref rid="B104" ref-type="bibr">104</xref>].</p><p>The bevy of inhibitors of eIF4E and also eIF4A (see below) [<xref rid="B105" ref-type="bibr">105</xref>] provides an intriguing opportunity to cope with the pernicious problem of tumour heterogeneity in targeting cancer. It is well established that most cancers consist of heterogeneous tumour types&#x000a0;with different genetic aberrations [<xref rid="B106" ref-type="bibr">106</xref>,<xref rid="B107" ref-type="bibr">107</xref>]. Consequently, personalized medicine/targeted monotherapies are effective only for relatively short times (less than 1 year) in the majority of cancers, as they lead to the selection of pre-existing intrinsically resistant sub-population of cells (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref rid="B107" ref-type="bibr">107</xref>]. For example, mammary tumours are considered clinically HER2 (human epidermal growth factor receptor 2)-positive when immunohistochemical analysis identifies as few as 30% of HER2-expressing cells [<xref rid="B108" ref-type="bibr">108</xref>], whereas the cut-off for EGFR (epidermal growth factor receptor) positivity is only 1% [<xref rid="B109" ref-type="bibr">109</xref>]. Therefore, only a small fraction of tumour cells are required to strain positive by IHC (immunohistochemistry) in order to be considered for clinically targeted therapy [<xref rid="B110" ref-type="bibr">110</xref>]. Although the treatment of cancer with the EGFR/HER2 inhibitor Lapatinib provides initial benefit, the presence of tumour cells having acquired EGFR/HER2 independence or contain other mutations (i.e. PI3K mutation, TSC2 loss, PTEN loss, eIF4E amplification, etc.) will eventually lead to resistance to treatment. One possible solution is to employ a combination of drugs directed against two or more targets which can lead to enhanced efficacy; however, this approach also generally leads to additive or even synergistic toxicity [<xref rid="B111" ref-type="bibr">111</xref>,<xref rid="B112" ref-type="bibr">112</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><title>Targeting eIF4E in tumour heterogeneity</title><p>A schematic diagram illustrating a simplified version of diversity within a hypothetical heterogeneous tumour. Sub-populations of cells expressing HER2 (green), ER&#x003b1; (blue) or presenting BRCA1/2 mutations (red) are shown. In contrast, all tumour cells contain elevated eIF4E. The tumours containing the indicated targets are treated in the clinic by the corresponding drugs listed in the figure. We hypothesize that direct eIF4E inhibitors will target all types&#x000a0;of tumour cells, regardless of their genetic make-up.</p></caption><graphic xlink:href="bst0430763fig3"/></fig><p>In general, many therapeutic cancer targets display similar heterogeneous expression patterns; however, Ramon et al. [<xref rid="B113" ref-type="bibr">113</xref>] obtained IHC data demonstrating a homogenous distribution of elevated eIF4E and 4E-BP and their phosphorylated forms in breast cancer. If this striking observation were to be repeated in other tumours, this would provide an intriguing opportunity to use inhibitors of eIF4F as monotherapies for cancer. Consistent with this idea, recent studies have found that an inhibitor of eIF4F suppressed B-Raf (B-Raf proto-oncogene serine/threonine-protein kinase) resistant melanoma [<xref rid="B114" ref-type="bibr">114</xref>]. In addition to the inhibitors of eIF4E described above, several anti-eIF4A natural compounds were discovered, which exhibit potent inhibition of proliferation and anti-tumorigenic activities [<xref rid="B105" ref-type="bibr">105</xref>]. These compounds include, silvestrol, hippuristanol and pateamine A. Notably, Pelletier's group showed that multiple myeloma cancer cells which are resistant to standard therapy could be eliminated by the eIF4A inhibitor silvestrol [<xref rid="B105" ref-type="bibr">105</xref>]. Taken together, these experiments imply that a highly promising application of single eIF4F inhibitors for cancer treatment is to combat drug resistance.</p><p>In addition to cancer, eIF4E has been implicated in neurodevelopmental diseases, in which translation is dysregulated, such as autism and fragile-X syndrome (FXS). Notably, drugs that are being developed for cancer, such as 4EGI, were shown to correct autistic-like deficits in mice [<xref rid="B115" ref-type="bibr">115</xref>] and cercosporamide reversed many of the FXS-like symptoms in mice [<xref rid="B116" ref-type="bibr">116</xref>]. In summary, the cap-binding protein eIF4E plays a critical role in cell homoeostasis in health and disease. It is hoped that some of the currently tested candidate drugs or their derivatives that inhibit eIF4E activity will prove effective as anti-cancer drugs. It is also clear that the accumulated exhaustive knowledge of the structure and function of eIF4E and its regulators will prove to be instrumental in designing effective drugs against cancer.</p></sec></body><back><ack><p>We thank Nathaniel Robichaud and Christopher Rouya for their comments on the manuscript. Nahum Sonenberg is a Howard Hughes Medical Institute Senior International Scholar.</p></ack><fn-group><fn fn-type="presented-at"><p>The Centenary Award</p></fn></fn-group><sec><title>Funding</title><p>This work was supported by <funding-source id="gs1">the Susan G. Komen Breast Cancer Foundation</funding-source> [<award-id rid="gs1">KGMS IIR12224057</award-id>], <funding-source id="gs2">the Canadian Institute of Health Research</funding-source> [<award-id rid="gs2">MOP-7214</award-id>], <funding-source id="gs3">Howard Hughes Medical Institute</funding-source> [<award-id rid="gs3">HHMI 55007654</award-id>], and <funding-source id="gs4">the Canadian Cancer Society Research Institute</funding-source> [<award-id rid="gs4">CCSRI 702317</award-id>].</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">ASO</term><def><p>anti-sense oligonucleotide</p></def></def-item><def-item><term id="uid2">asTORi</term><def><p>active-site TOR inhibitor</p></def></def-item><def-item><term id="uid3">eIF</term><def><p>eukaryotic translation initiation factor</p></def></def-item><def-item><term id="uid4">4E-BPs</term><def><p>eIF4E-binding proteins</p></def></def-item><def-item><term id="uid5">EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item><def-item><term id="uid6">EMT</term><def><p>epithelial-to-mesenchymal transition</p></def></def-item><def-item><term id="uid7">ERK</term><def><p>extracellular signal regulated kinase</p></def></def-item><def-item><term id="uid8">FXS</term><def><p>fragile-X syndrome</p></def></def-item><def-item><term id="uid9">HER2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term id="uid10">IHC</term><def><p>immunohistochemistry</p></def></def-item><def-item><term id="uid11">MAPK</term><def><p>activated protein kinase</p></def></def-item><def-item><term id="uid12">MMP-3</term><def><p>matrix metalloproteinase-3</p></def></def-item><def-item><term id="uid13">Mnk</term><def><p>MAPK-interacting kinases</p></def></def-item><def-item><term id="uid14">mTOR</term><def><p>mechanistic/mammalian target of rapamycin</p></def></def-item><def-item><term id="uid15">mTORC1/2</term><def><p>mTOR complex 1/2</p></def></def-item><def-item><term id="uid16">PABP</term><def><p>poly (A)-binding protein</p></def></def-item><def-item><term id="uid17">PH</term><def><p>pleckstrin homology</p></def></def-item><def-item><term id="uid18">PI3K</term><def><p>phosphoinositide 3-kinase</p></def></def-item><def-item><term id="uid19">PIN</term><def><p>prostate intraepithelial neoplasia</p></def></def-item><def-item><term id="uid20">PIP<sub>2</sub></term><def><p>phosphatidyl inositol 3,4</p></def></def-item><def-item><term id="uid21">PIP<sub>3</sub></term><def><p>phosphatidyl inositol 3,4,5</p></def></def-item><def-item><term id="uid22">PTEN</term><def><p>phosphatase and tensin homologue on chromosome 10</p></def></def-item><def-item><term id="uid23">TGF&#x003b2;</term><def><p>tumour growth factor &#x003b2;; TOP, terminal oligo pyrimidine</p></def></def-item><def-item><term id="uid24">TSC2</term><def><p>tuberous sclerosis complex 2</p></def></def-item><def-item><term id="uid25">VEGF</term><def><p>vascular endothelial growth factor</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>M.B.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Hershey</surname><given-names>J.</given-names></name></person-group><article-title>Translation Control in Biology and Medicine</article-title><source>Cold Spring Harbor Monograph Series 48</source><year>2007</year><publisher-loc>NY</publisher-loc><publisher-name>Cold Spring Harbor</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name><name><surname>Asano</surname><given-names>K.</given-names></name><name><surname>Olsen</surname><given-names>D.S.</given-names></name><name><surname>Phan</surname><given-names>L.</given-names></name><name><surname>Nielsen</surname><given-names>K.H.</given-names></name><name><surname>Valasek</surname><given-names>L.</given-names></name></person-group><article-title>Study of translational control of eukaryotic gene expression using yeast</article-title><source>Ann. N.Y. Acad. Sci.</source><year>2004</year><volume>1038</volume><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1196/annals.1315.012</pub-id><pub-id pub-id-type="pmid">15838098</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dever</surname><given-names>T.E.</given-names></name><name><surname>Green</surname><given-names>R.</given-names></name></person-group><article-title>The elongation, termination, and recycling phases of translation in eukaryotes</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2012</year><volume>4</volume><fpage>a013706</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a013706</pub-id><pub-id pub-id-type="pmid">22751155</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>R.J.</given-names></name><name><surname>Hellen</surname><given-names>C.U.</given-names></name><name><surname>Pestova</surname><given-names>T.V.</given-names></name></person-group><article-title>The mechanism of eukaryotic translation initiation and principles of its regulation</article-title><source>N. Rev. Mol. Cell Biol.</source><year>2010</year><volume>11</volume><fpage>113</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1038/nrm2838</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name></person-group><article-title>Regulation of translation initiation in eukaryotes: mechanisms and biological targets</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>731</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.042</pub-id><pub-id pub-id-type="pmid">19239892</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topisirovic</surname><given-names>I.</given-names></name><name><surname>Svitkin</surname><given-names>Y.V.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Shatkin</surname><given-names>A.J.</given-names></name></person-group><article-title>Cap and cap-binding proteins in the control of gene expression</article-title><source>Wiley Interdiscip. Rev. RNA</source><year>2011</year><volume>2</volume><fpage>277</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1002/wrna.52</pub-id><pub-id pub-id-type="pmid">21957010</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>A.C.</given-names></name><name><surname>Raught</surname><given-names>B.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation</article-title><source>Annu. Rev. Biochem.</source><year>1999</year><volume>68</volume><fpage>913</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.68.1.913</pub-id><pub-id pub-id-type="pmid">10872469</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsyan</surname><given-names>A.</given-names></name><name><surname>Svitkin</surname><given-names>Y.</given-names></name><name><surname>Shahbazian</surname><given-names>D.</given-names></name><name><surname>Gkogkas</surname><given-names>C.</given-names></name><name><surname>Lasko</surname><given-names>P.</given-names></name><name><surname>Merrick</surname><given-names>W.C.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>mRNA helicases: the tacticians of translational control</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2011</year><volume>12</volume><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/nrm3083</pub-id><pub-id pub-id-type="pmid">21427765</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name></person-group><article-title>The scanning mechanism of eukaryotic translation initiation</article-title><source>Annu. Rev. Biochem.</source><year>2014</year><volume>83</volume><fpage>779</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035802</pub-id><pub-id pub-id-type="pmid">24499181</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarun</surname><given-names>S.Z.</given-names><suffix>Jr</suffix></name><name><surname>Sachs</surname><given-names>A.B.</given-names></name></person-group><article-title>Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G</article-title><source>EMBO J.</source><year>1996</year><volume>15</volume><fpage>7168</fpage><lpage>7177</lpage><pub-id pub-id-type="pmid">9003792</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahvejian</surname><given-names>A.</given-names></name><name><surname>Svitkin</surname><given-names>Y.V.</given-names></name><name><surname>Sukarieh</surname><given-names>R.</given-names></name><name><surname>M'Boutchou</surname><given-names>M.N.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms</article-title><source>Genes Dev.</source><year>2005</year><volume>19</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1101/gad.1262905</pub-id><pub-id pub-id-type="pmid">15630022</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>M.</given-names></name><name><surname>Robichaud</surname><given-names>N.</given-names></name><name><surname>Hulea</surname><given-names>L.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Topisirovic</surname><given-names>I.</given-names></name></person-group><article-title>Targeting the translation machinery in cancer</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nrd4505</pub-id><pub-id pub-id-type="pmid">25743081</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>J.R.</given-names></name><name><surname>Konicek</surname><given-names>B.W.</given-names></name><name><surname>Carter</surname><given-names>J.H.</given-names></name><name><surname>Marcusson</surname><given-names>E.G.</given-names></name></person-group><article-title>Targeting the eukaryotic translation initiation factor 4E for cancer therapy</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>631</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5635</pub-id><pub-id pub-id-type="pmid">18245460</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrke</surname><given-names>L.</given-names></name><name><surname>Auron</surname><given-names>P.E.</given-names></name><name><surname>Quigley</surname><given-names>G.J.</given-names></name><name><surname>Rich</surname><given-names>A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>5'-Conformation of capped alfalfa mosaic virus ribonucleic acid 4 may reflect its independence of the cap structure or of cap-binding protein for efficient translation</article-title><source>Biochemistry</source><year>1983</year><volume>22</volume><fpage>5157</fpage><lpage>5164</lpage><pub-id pub-id-type="doi">10.1021/bi00291a015</pub-id><pub-id pub-id-type="pmid">6317016</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payvar</surname><given-names>F.</given-names></name><name><surname>Schimke</surname><given-names>R.T.</given-names></name></person-group><article-title>Methylmercury hydroxide enhancement of translation and transcription of ovalbumin and conalbumin mRNA's</article-title><source>J. Biol. Chem.</source><year>1979</year><volume>254</volume><fpage>7636</fpage><lpage>7642</lpage><pub-id pub-id-type="pmid">89113</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency</article-title><source>Cell</source><year>1985</year><volume>40</volume><fpage>515</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(85)90200-4</pub-id><pub-id pub-id-type="pmid">2982496</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossen</surname><given-names>B.</given-names></name><name><surname>Caughman</surname><given-names>S.W.</given-names></name><name><surname>Harford</surname><given-names>J.B.</given-names></name><name><surname>Klausner</surname><given-names>R.D.</given-names></name><name><surname>Hentze</surname><given-names>M.W.</given-names></name></person-group><article-title>Translational repression by a complex between the iron-responsive element of ferritin mRNA and its specific cytoplasmic binding protein is position-dependent <italic>in&#x000a0;vivo</italic></article-title><source>EMBO J.</source><year>1990</year><volume>9</volume><fpage>4127</fpage><lpage>4133</lpage><pub-id pub-id-type="pmid">1701143</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagliocco</surname><given-names>F.A.</given-names></name><name><surname>Vega Laso</surname><given-names>M.R.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Tuite</surname><given-names>M.F.</given-names></name><name><surname>McCarthy</surname><given-names>J.E.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>The influence of 5'-secondary structures upon ribosome binding to mRNA during translation in yeast</article-title><source>J. Biol. Chem.</source><year>1993</year><volume>268</volume><fpage>26522</fpage><lpage>26530</lpage><pub-id pub-id-type="pmid">8253781</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babendure</surname><given-names>J.R.</given-names></name><name><surname>Babendure</surname><given-names>J.L.</given-names></name><name><surname>Ding</surname><given-names>J.H.</given-names></name><name><surname>Tsien</surname><given-names>R.Y.</given-names></name></person-group><article-title>Control of mammalian translation by mRNA structure near caps</article-title><source>RNA</source><year>2006</year><volume>12</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1261/rna.2309906</pub-id><pub-id pub-id-type="pmid">16540693</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozak</surname><given-names>M.</given-names></name></person-group><article-title>Influences of mRNA secondary structure on initiation by eukaryotic ribosomes</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>1986</year><volume>83</volume><fpage>2850</fpage><lpage>2854</lpage><pub-id pub-id-type="doi">10.1073/pnas.83.9.2850</pub-id><pub-id pub-id-type="pmid">3458245</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koromilas</surname><given-names>A.E.</given-names></name><name><surname>Lazaris-Karatzas</surname><given-names>A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E</article-title><source>EMBO J.</source><year>1992</year><volume>11</volume><fpage>4153</fpage><lpage>4158</lpage><pub-id pub-id-type="pmid">1396596</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svitkin</surname><given-names>Y.V.</given-names></name><name><surname>Pause</surname><given-names>A.</given-names></name><name><surname>Haghighat</surname><given-names>A.</given-names></name><name><surname>Pyronnet</surname><given-names>S.</given-names></name><name><surname>Witherell</surname><given-names>G.</given-names></name><name><surname>Belsham</surname><given-names>G.J.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure</article-title><source>RNA</source><year>2001</year><volume>7</volume><fpage>382</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1017/S135583820100108X</pub-id><pub-id pub-id-type="pmid">11333019</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feoktistova</surname><given-names>K.</given-names></name><name><surname>Tuvshintogs</surname><given-names>E.</given-names></name><name><surname>Do</surname><given-names>A.</given-names></name><name><surname>Fraser</surname><given-names>C.S.</given-names></name></person-group><article-title>Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2013</year><volume>110</volume><fpage>13339</fpage><lpage>13344</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303781110</pub-id><pub-id pub-id-type="pmid">23901100</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreen</surname><given-names>C.C.</given-names></name><name><surname>Chantranupong</surname><given-names>L.</given-names></name><name><surname>Keys</surname><given-names>H.R.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Gray</surname><given-names>N.S.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>A unifying model for mTORC1-mediated regulation of mRNA translation</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nature11083</pub-id><pub-id pub-id-type="pmid">22552098</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>A.C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Edlind</surname><given-names>M.P.</given-names></name><name><surname>Ingolia</surname><given-names>N.T.</given-names></name><name><surname>Janes</surname><given-names>M.R.</given-names></name><name><surname>Sher</surname><given-names>A.</given-names></name><name><surname>Shi</surname><given-names>E.Y.</given-names></name><name><surname>Stumpf</surname><given-names>C.R.</given-names></name><name><surname>Christensen</surname><given-names>C.</given-names></name><name><surname>Bonham</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>The translational landscape of mTOR signalling steers cancer initiation and metastasis</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nature10912</pub-id><pub-id pub-id-type="pmid">22367541</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miloslavski</surname><given-names>R.</given-names></name><name><surname>Cohen</surname><given-names>E.</given-names></name><name><surname>Avraham</surname><given-names>A.</given-names></name><name><surname>Iluz</surname><given-names>Y.</given-names></name><name><surname>Hayouka</surname><given-names>Z.</given-names></name><name><surname>Kasir</surname><given-names>J.</given-names></name><name><surname>Mudhasani</surname><given-names>R.</given-names></name><name><surname>Jones</surname><given-names>S.N.</given-names></name><name><surname>Cybulski</surname><given-names>N.</given-names></name><name><surname>Ruegg</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner</article-title><source>J. Mol. Cell Biol.</source><year>2014</year><volume>6</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mju008</pub-id><pub-id pub-id-type="pmid">24627160</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyuhas</surname><given-names>O.</given-names></name><name><surname>Kahan</surname><given-names>T.</given-names></name></person-group><article-title>The race to decipher the top secrets of TOP mRNAs</article-title><source>Biochim. Biophys. Acta.</source><year>2014</year><volume>1849</volume><fpage>801</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.08.015</pub-id><pub-id pub-id-type="pmid">25234618</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mader</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Pause</surname><given-names>A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins</article-title><source>Mol. Cell. Biol.</source><year>1995</year><volume>15</volume><fpage>4990</fpage><lpage>4997</lpage><pub-id pub-id-type="pmid">7651417</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pause</surname><given-names>A.</given-names></name><name><surname>Belsham</surname><given-names>G.J.</given-names></name><name><surname>Gingras</surname><given-names>A.C.</given-names></name><name><surname>Donze</surname><given-names>O.</given-names></name><name><surname>Lin</surname><given-names>T.A.</given-names></name><name><surname>Lawrence</surname><given-names>J.C.</given-names><suffix>Jr</suffix></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function</article-title><source>Nature</source><year>1994</year><volume>371</volume><fpage>762</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/371762a0</pub-id><pub-id pub-id-type="pmid">7935836</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulin</surname><given-names>F.</given-names></name><name><surname>Gingras</surname><given-names>A.C.</given-names></name><name><surname>Olsen</surname><given-names>H.</given-names></name><name><surname>Chevalier</surname><given-names>S.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>14002</fpage><lpage>14007</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.22.14002</pub-id><pub-id pub-id-type="pmid">9593750</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>N.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Upstream and downstream of mTOR</article-title><source>Genes Dev.</source><year>2004</year><volume>18</volume><fpage>1926</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1101/gad.1212704</pub-id><pub-id pub-id-type="pmid">15314020</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laplante</surname><given-names>M.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>mTOR signaling in growth control and disease</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>274</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.017</pub-id><pub-id pub-id-type="pmid">22500797</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caron</surname><given-names>E.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Matsuoka</surname><given-names>Y.</given-names></name><name><surname>Ashton-Beaucage</surname><given-names>D.</given-names></name><name><surname>Therrien</surname><given-names>M.</given-names></name><name><surname>Lemieux</surname><given-names>S.</given-names></name><name><surname>Perreault</surname><given-names>C.</given-names></name><name><surname>Roux</surname><given-names>P.P.</given-names></name><name><surname>Kitano</surname><given-names>H.</given-names></name></person-group><article-title>A comprehensive map of the mTOR signaling network</article-title><source>Mol. Syst. Biol.</source><year>2010</year><volume>6</volume><fpage>453</fpage><pub-id pub-id-type="doi">10.1038/msb.2010.108</pub-id><pub-id pub-id-type="pmid">21179025</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wullschleger</surname><given-names>S.</given-names></name><name><surname>Loewith</surname><given-names>R.</given-names></name><name><surname>Hall</surname><given-names>M.N.</given-names></name></person-group><article-title>TOR signaling in growth and metabolism</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.016</pub-id><pub-id pub-id-type="pmid">16469695</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.H.</given-names></name><name><surname>Sarbassov</surname><given-names>D.D.</given-names></name><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Latek</surname><given-names>R.R.</given-names></name><name><surname>Guntur</surname><given-names>K.V.</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H.</given-names></name><name><surname>Tempst</surname><given-names>P.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR</article-title><source>Mol. Cell</source><year>2003</year><volume>11</volume><fpage>895</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00114-X</pub-id><pub-id pub-id-type="pmid">12718876</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.M.</given-names></name><name><surname>Blenis</surname><given-names>J.</given-names></name></person-group><article-title>Molecular mechanisms of mTOR-mediated translational control</article-title><source>Nat. Rev. Mol. Cell. Biol.</source><year>2009</year><volume>10</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1038/nrm2672</pub-id><pub-id pub-id-type="pmid">19339977</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Peled</surname><given-names>L.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Regulation of mTORC1 by amino acids</article-title><source>Trends Cell Biol.</source><year>2014</year><volume>24</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2014.03.003</pub-id><pub-id pub-id-type="pmid">24698685</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantley</surname><given-names>L.C.</given-names></name></person-group><article-title>The phosphoinositide 3-kinase pathway</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1655</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1126/science.296.5573.1655</pub-id><pub-id pub-id-type="pmid">12040186</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>T.L.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name></person-group><article-title>PI3K pathway alterations in cancer: variations on a theme</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>5497</fpage><lpage>5510</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.245</pub-id><pub-id pub-id-type="pmid">18794884</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>L.R.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Boudeau</surname><given-names>J.</given-names></name><name><surname>Pawlowski</surname><given-names>R.</given-names></name><name><surname>Wullschleger</surname><given-names>S.</given-names></name><name><surname>Deak</surname><given-names>M.</given-names></name><name><surname>Ibrahim</surname><given-names>A.F.</given-names></name><name><surname>Gourlay</surname><given-names>R.</given-names></name><name><surname>Magnuson</surname><given-names>M.A.</given-names></name><name><surname>Alessi</surname><given-names>D.R.</given-names></name></person-group><article-title>Identification of Protor as a novel Rictor-binding component of mTOR complex-2</article-title><source>Biochem. J.</source><year>2007</year><volume>405</volume><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1042/BJ20070540</pub-id><pub-id pub-id-type="pmid">17461779</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandel</surname><given-names>E.S.</given-names></name><name><surname>Hay</surname><given-names>N.</given-names></name></person-group><article-title>The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB</article-title><source>Exp. Cell Res.</source><year>1999</year><volume>253</volume><fpage>210</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1006/excr.1999.4690</pub-id><pub-id pub-id-type="pmid">10579924</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazil</surname><given-names>D.P.</given-names></name><name><surname>Hemmings</surname><given-names>B.A.</given-names></name></person-group><article-title>Ten years of protein kinase B signalling: a hard Akt to follow</article-title><source>Trends Biochem. Sci.</source><year>2001</year><volume>26</volume><fpage>657</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(01)01958-2</pub-id><pub-id pub-id-type="pmid">11701324</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>M.P.</given-names></name><name><surname>Woodgett</surname><given-names>J.R.</given-names></name></person-group><article-title>Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis</article-title><source>J. Mammary Gland Biol. Neoplasia</source><year>2001</year><volume>6</volume><fpage>83</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1023/A:1009520616247</pub-id><pub-id pub-id-type="pmid">11467455</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>D.D.</given-names></name><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Sengupta</surname><given-names>S.</given-names></name><name><surname>Sheen</surname><given-names>J.H.</given-names></name><name><surname>Hsu</surname><given-names>P.P.</given-names></name><name><surname>Bagley</surname><given-names>A.F.</given-names></name><name><surname>Markhard</surname><given-names>A.L.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB</article-title><source>Mol. Cell</source><year>2006</year><volume>22</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.03.029</pub-id><pub-id pub-id-type="pmid">16603397</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoki</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>K.L.</given-names></name></person-group><article-title>TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling</article-title><source>Nat. Cell Biol.</source><year>2002</year><volume>4</volume><fpage>648</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/ncb839</pub-id><pub-id pub-id-type="pmid">12172553</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>J.</given-names></name><name><surname>Beutler</surname><given-names>K.</given-names></name><name><surname>Knepper</surname><given-names>M.A.</given-names></name><name><surname>Vehaskari</surname><given-names>V.M.</given-names></name></person-group><article-title>Upregulation of renal BSC1 and TSC in prenatally programmed hypertension</article-title><source>Am. J. Physiol. Renal Physiol.</source><year>2002</year><volume>283</volume><fpage>F202</fpage><lpage>F206</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00358.2001</pub-id><pub-id pub-id-type="pmid">12060603</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dibble</surname><given-names>C.C.</given-names></name><name><surname>Elis</surname><given-names>W.</given-names></name><name><surname>Menon</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>W.</given-names></name><name><surname>Klekota</surname><given-names>J.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Finan</surname><given-names>P.M.</given-names></name><name><surname>Kwiatkowski</surname><given-names>D.J.</given-names></name><name><surname>Murphy</surname><given-names>L.O.</given-names></name><name><surname>Manning</surname><given-names>B.D.</given-names></name></person-group><article-title>TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1</article-title><source>Mol. Cell</source><year>2012</year><volume>47</volume><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.06.009</pub-id><pub-id pub-id-type="pmid">22795129</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>A.C.</given-names></name><name><surname>Gygi</surname><given-names>S.P.</given-names></name><name><surname>Raught</surname><given-names>B.</given-names></name><name><surname>Polakiewicz</surname><given-names>R.D.</given-names></name><name><surname>Abraham</surname><given-names>R.T.</given-names></name><name><surname>Hoekstra</surname><given-names>M.F.</given-names></name><name><surname>Aebersold</surname><given-names>R.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism</article-title><source>Genes Dev.</source><year>1999</year><volume>13</volume><fpage>1422</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1101/gad.13.11.1422</pub-id><pub-id pub-id-type="pmid">10364159</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>A.C.</given-names></name><name><surname>Kennedy</surname><given-names>S.G.</given-names></name><name><surname>O'Leary</surname><given-names>M.A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Hay</surname><given-names>N.</given-names></name></person-group><article-title>4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway</article-title><source>Genes Dev.</source><year>1998</year><volume>12</volume><fpage>502</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1101/gad.12.4.502</pub-id><pub-id pub-id-type="pmid">9472019</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamane</surname><given-names>Y.</given-names></name><name><surname>Petroulakis</surname><given-names>E.</given-names></name><name><surname>Martineau</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>T.A.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Rajasekhar</surname><given-names>V.K.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e242</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0000242</pub-id><pub-id pub-id-type="pmid">17311107</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Nadon</surname><given-names>R.</given-names></name></person-group><article-title>Identification of differential translation in genome wide studies</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year><volume>107</volume><fpage>21487</fpage><lpage>21492</lpage><pub-id pub-id-type="doi">10.1073/pnas.1006821107</pub-id><pub-id pub-id-type="pmid">21115840</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaris-Karatzas</surname><given-names>A.</given-names></name><name><surname>Montine</surname><given-names>K.S.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap</article-title><source>Nature</source><year>1990</year><volume>345</volume><fpage>544</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/345544a0</pub-id><pub-id pub-id-type="pmid">2348862</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaris-Karatzas</surname><given-names>A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts</article-title><source>Mol. Cell. Biol.</source><year>1992</year><volume>12</volume><fpage>1234</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">1532049</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdulov</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Michalek</surname><given-names>V.</given-names></name><name><surname>Burrichter</surname><given-names>D.</given-names></name><name><surname>Peterson</surname><given-names>M.</given-names></name><name><surname>Perlman</surname><given-names>D.M.</given-names></name><name><surname>Manivel</surname><given-names>J.C.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Yee</surname><given-names>D.</given-names></name><name><surname>Bitterman</surname><given-names>P.B.</given-names></name><name><surname>Polunovsky</surname><given-names>V.A.</given-names></name></person-group><article-title>Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells</article-title><source>Cancer Cell</source><year>2004</year><volume>5</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.05.024</pub-id><pub-id pub-id-type="pmid">15193258</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>D.</given-names></name><name><surname>Kaspar</surname><given-names>R.</given-names></name><name><surname>Rosenwald</surname><given-names>I.</given-names></name><name><surname>Gehrke</surname><given-names>L.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>1996</year><volume>93</volume><fpage>1065</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.3.1065</pub-id><pub-id pub-id-type="pmid">8577715</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>R.J.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Translational Control in Cancer Development and Progression</article-title><source>Cold Spring Harbor Monograph Archive</source><year>2007</year><publisher-loc>Cold Spring Harbor, NY</publisher-loc></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinker-Schaeffer</surname><given-names>C.W.</given-names></name><name><surname>Graff</surname><given-names>J.R.</given-names></name><name><surname>De Benedetti</surname><given-names>A.</given-names></name><name><surname>Zimmer</surname><given-names>S.G.</given-names></name><name><surname>Rhoads</surname><given-names>R.E.</given-names></name></person-group><article-title>Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts</article-title><source>Int. J. Cancer</source><year>1993</year><volume>55</volume><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910550525</pub-id><pub-id pub-id-type="pmid">8244582</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendel</surname><given-names>H.G.</given-names></name><name><surname>De Stanchina</surname><given-names>E.</given-names></name><name><surname>Fridman</surname><given-names>J.S.</given-names></name><name><surname>Malina</surname><given-names>A.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name><name><surname>Kogan</surname><given-names>S.</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy</article-title><source>Nature</source><year>2004</year><volume>428</volume><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature02369</pub-id><pub-id pub-id-type="pmid">15029198</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggero</surname><given-names>D.</given-names></name><name><surname>Montanaro</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Londei</surname><given-names>P.</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C.</given-names></name><name><surname>Pandolfi</surname><given-names>P.P.</given-names></name></person-group><article-title>The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>484</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nm1042</pub-id><pub-id pub-id-type="pmid">15098029</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waskiewicz</surname><given-names>A.J.</given-names></name><name><surname>Johnson</surname><given-names>J.C.</given-names></name><name><surname>Penn</surname><given-names>B.</given-names></name><name><surname>Mahalingam</surname><given-names>M.</given-names></name><name><surname>Kimball</surname><given-names>S.R.</given-names></name><name><surname>Cooper</surname><given-names>J.A.</given-names></name></person-group><article-title>Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 <italic>in&#x000a0;vivo</italic></article-title><source>Mol. Cell. Biol.</source><year>1999</year><volume>19</volume><fpage>1871</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">10022874</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukunaga</surname><given-names>R.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name></person-group><article-title>MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates</article-title><source>EMBO J.</source><year>1997</year><volume>16</volume><fpage>1921</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.8.1921</pub-id><pub-id pub-id-type="pmid">9155018</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topisirovic</surname><given-names>I.</given-names></name><name><surname>Ruiz-Gutierrez</surname><given-names>M.</given-names></name><name><surname>Borden</surname><given-names>K.L.</given-names></name></person-group><article-title>Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>8639</fpage><lpage>8642</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2677</pub-id><pub-id pub-id-type="pmid">15574771</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendel</surname><given-names>H.G.</given-names></name><name><surname>Silva</surname><given-names>R.L.</given-names></name><name><surname>Malina</surname><given-names>A.</given-names></name><name><surname>Mills</surname><given-names>J.R.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Ueda</surname><given-names>T.</given-names></name><name><surname>Watanabe-Fukunaga</surname><given-names>R.</given-names></name><name><surname>Fukunaga</surname><given-names>R.</given-names></name><name><surname>Teruya-Feldstein</surname><given-names>J.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>Dissecting eIF4E action in tumorigenesis</article-title><source>Genes Dev.</source><year>2007</year><volume>21</volume><fpage>3232</fpage><lpage>3237</lpage><pub-id pub-id-type="doi">10.1101/gad.1604407</pub-id><pub-id pub-id-type="pmid">18055695</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furic</surname><given-names>L.</given-names></name><name><surname>Rong</surname><given-names>L.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Koumakpayi</surname><given-names>I.H.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Brueschke</surname><given-names>A.</given-names></name><name><surname>Petroulakis</surname><given-names>E.</given-names></name><name><surname>Robichaud</surname><given-names>N.</given-names></name><name><surname>Pollak</surname><given-names>M.</given-names></name><name><surname>Gaboury</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year><volume>107</volume><fpage>14134</fpage><lpage>14139</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005320107</pub-id><pub-id pub-id-type="pmid">20679199</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robichaud</surname><given-names>N.</given-names></name><name><surname>Del Rincon</surname><given-names>S.V.</given-names></name><name><surname>Huor</surname><given-names>B.</given-names></name><name><surname>Alain</surname><given-names>T.</given-names></name><name><surname>Petruccelli</surname><given-names>L.A.</given-names></name><name><surname>Hearnden</surname><given-names>J.</given-names></name><name><surname>Goncalves</surname><given-names>C.</given-names></name><name><surname>Grotegut</surname><given-names>S.</given-names></name><name><surname>Spruck</surname><given-names>C.H.</given-names></name><name><surname>Furic</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3</article-title><source>Oncogene</source><year>2014</year><volume>34</volume><fpage>2032</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.146</pub-id><pub-id pub-id-type="pmid">24909168</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotman</surname><given-names>L.C.</given-names></name><name><surname>Niki</surname><given-names>M.</given-names></name><name><surname>Dotan</surname><given-names>Z.A.</given-names></name><name><surname>Koutcher</surname><given-names>J.A.</given-names></name><name><surname>Cristofano</surname><given-names>A.</given-names></name><name><surname>Xiao</surname><given-names>A.</given-names></name><name><surname>Khoo</surname><given-names>A.S.</given-names></name><name><surname>Roy-Burman</surname><given-names>P.</given-names></name><name><surname>Greenberg</surname><given-names>N.M.</given-names></name><name><surname>Dyke</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Pten dose dictates cancer progression in the prostate</article-title><source>PLoS Biol.</source><year>2003</year><volume>1</volume><pub-id pub-id-type="doi">10.1371/journal.pbio.0000059</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konicek</surname><given-names>B.W.</given-names></name><name><surname>Stephens</surname><given-names>J.R.</given-names></name><name><surname>McNulty</surname><given-names>A.M.</given-names></name><name><surname>Robichaud</surname><given-names>N.</given-names></name><name><surname>Peery</surname><given-names>R.B.</given-names></name><name><surname>Dumstorf</surname><given-names>C.A.</given-names></name><name><surname>Dowless</surname><given-names>M.S.</given-names></name><name><surname>Iversen</surname><given-names>P.W.</given-names></name><name><surname>Parsons</surname><given-names>S.</given-names></name><name><surname>Ellis</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>1849</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3298</pub-id><pub-id pub-id-type="pmid">21233335</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>Z.</given-names></name><name><surname>Robert</surname><given-names>F.</given-names></name><name><surname>Jr</surname><given-names>J.A.</given-names></name><name><surname>Muller</surname><given-names>W.J.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name></person-group><article-title>eIF4F suppression in breast cancer affects maintenance and progression</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>861</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.105</pub-id><pub-id pub-id-type="pmid">22484424</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedl</surname><given-names>P.</given-names></name><name><surname>Alexander</surname><given-names>S.</given-names></name></person-group><article-title>Cancer invasion and the microenvironment: plasticity and reciprocity</article-title><source>Cell</source><year>2011</year><volume>147</volume><fpage>992</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.11.016</pub-id><pub-id pub-id-type="pmid">22118458</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lamouille</surname><given-names>S.</given-names></name><name><surname>Derynck</surname><given-names>R.</given-names></name></person-group><article-title>TGF-beta-induced epithelial to mesenchymal transition</article-title><source>Cell Res.</source><year>2009</year><volume>19</volume><fpage>156</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/cr.2009.5</pub-id><pub-id pub-id-type="pmid">19153598</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proud</surname><given-names>C.G.</given-names></name></person-group><article-title>Mnks, eIF4E phosphorylation and cancer</article-title><source>Biochim. Biophys. Acta</source><year>2014</year><fpage>766</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">25450520</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armengol</surname><given-names>G.</given-names></name><name><surname>Rojo</surname><given-names>F.</given-names></name><name><surname>Castellvi</surname><given-names>J.</given-names></name><name><surname>Iglesias</surname><given-names>C.</given-names></name><name><surname>Cuatrecasas</surname><given-names>M.</given-names></name><name><surname>Pons</surname><given-names>B.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Cajal</surname><given-names>S.</given-names></name></person-group><article-title>funnel factor</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>7551</fpage><lpage>7555</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0881</pub-id><pub-id pub-id-type="pmid">17699757</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Graff</surname><given-names>J.</given-names></name><name><surname>Ruggero</surname><given-names>D.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Targeting the eIF4F translation initiation complex: a critical nexus for cancer development</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>250</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2789</pub-id><pub-id pub-id-type="pmid">25593033</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Kang</surname><given-names>S.A.</given-names></name><name><surname>Thoreen</surname><given-names>C.C.</given-names></name><name><surname>Hur</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>J.W.</given-names></name><name><surname>Markhard</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Sim</surname><given-names>T.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name><name><surname>Gray</surname><given-names>N.S.</given-names></name></person-group><article-title>Development of ATP-competitive mTOR inhibitors</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>821</volume><fpage>447</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-430-8</pub-id><pub-id pub-id-type="pmid">22125084</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>M.E.</given-names></name><name><surname>Apsel</surname><given-names>B.</given-names></name><name><surname>Uotila</surname><given-names>A.</given-names></name><name><surname>Loewith</surname><given-names>R.</given-names></name><name><surname>Knight</surname><given-names>Z.A.</given-names></name><name><surname>Ruggero</surname><given-names>D.</given-names></name><name><surname>Shokat</surname><given-names>K.M.</given-names></name></person-group><article-title>Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</article-title><source>PLoS Biol.</source><year>2009</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pbio.1000038</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilic</surname><given-names>N.</given-names></name><name><surname>Utermark</surname><given-names>T.</given-names></name><name><surname>Widlund</surname><given-names>H.R.</given-names></name><name><surname>Roberts</surname><given-names>T.M.</given-names></name></person-group><article-title>PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2011</year><volume>108</volume><fpage>E699</fpage><lpage>E708</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108237108</pub-id><pub-id pub-id-type="pmid">21876152</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cope</surname><given-names>C.L.</given-names></name><name><surname>Gilley</surname><given-names>R.</given-names></name><name><surname>Balmanno</surname><given-names>K.</given-names></name><name><surname>Sale</surname><given-names>M.J.</given-names></name><name><surname>Howarth</surname><given-names>K.D.</given-names></name><name><surname>Hampson</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>P.D.</given-names></name><name><surname>Guichard</surname><given-names>S.M.</given-names></name><name><surname>Cook</surname><given-names>S.J.</given-names></name></person-group><article-title>Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation</article-title><source>J. Cell Sci.</source><year>2014</year><volume>127</volume><fpage>788</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1242/jcs.137588</pub-id><pub-id pub-id-type="pmid">24363449</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alain</surname><given-names>T.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Topisirovic</surname><given-names>I.</given-names></name></person-group><article-title>mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio</article-title><source>Oncotarget</source><year>2012</year><volume>3</volume><fpage>1491</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">23455427</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>R.J.</given-names></name><name><surname>Topisirovic</surname><given-names>I.</given-names></name><name><surname>Alain</surname><given-names>T.</given-names></name><name><surname>Bidinosti</surname><given-names>M.</given-names></name><name><surname>Fonseca</surname><given-names>B.D.</given-names></name><name><surname>Petroulakis</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Selvaraj</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs</article-title><source>Science</source><year>2010</year><volume>328</volume><fpage>1172</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1126/science.1187532</pub-id><pub-id pub-id-type="pmid">20508131</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>J.R.</given-names></name><name><surname>Konicek</surname><given-names>B.W.</given-names></name><name><surname>Vincent</surname><given-names>T.M.</given-names></name><name><surname>Lynch</surname><given-names>R.L.</given-names></name><name><surname>Monteith</surname><given-names>D.</given-names></name><name><surname>Weir</surname><given-names>S.N.</given-names></name><name><surname>Schwier</surname><given-names>P.</given-names></name><name><surname>Capen</surname><given-names>A.</given-names></name><name><surname>Goode</surname><given-names>R.L.</given-names></name><name><surname>Dowless</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity</article-title><source>J. Clin. Invest.</source><year>2007</year><volume>117</volume><fpage>2638</fpage><lpage>2648</lpage><pub-id pub-id-type="doi">10.1172/JCI32044</pub-id><pub-id pub-id-type="pmid">17786246</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagiya</surname><given-names>A.</given-names></name><name><surname>Suyama</surname><given-names>E.</given-names></name><name><surname>Adachi</surname><given-names>H.</given-names></name><name><surname>Svitkin</surname><given-names>Y.V.</given-names></name><name><surname>Aza-Blanc</surname><given-names>P.</given-names></name><name><surname>Imataka</surname><given-names>H.</given-names></name><name><surname>Mikami</surname><given-names>S.</given-names></name><name><surname>Martineau</surname><given-names>Y.</given-names></name><name><surname>Ronai</surname><given-names>Z.A.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Translational homeostasis via the mRNA cap-binding protein, eIF4E</article-title><source>Mol. Cell</source><year>2012</year><volume>46</volume><fpage>847</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.04.004</pub-id><pub-id pub-id-type="pmid">22578813</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J.</given-names></name><name><surname>Lam</surname><given-names>F.</given-names></name><name><surname>Proud</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Targeting Mnks for cancer therapy</article-title><source>Oncotarget</source><year>2012</year><volume>3</volume><fpage>118</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">22392765</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knauf</surname><given-names>U.</given-names></name><name><surname>Tschopp</surname><given-names>C.</given-names></name><name><surname>Gram</surname><given-names>H.</given-names></name></person-group><article-title>Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2</article-title><source>Mol. Cell Biol.</source><year>2001</year><volume>21</volume><fpage>5500</fpage><lpage>5511</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.16.5500-5511.2001</pub-id><pub-id pub-id-type="pmid">11463832</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konicek</surname><given-names>B.W.</given-names></name><name><surname>Dumstorf</surname><given-names>C.A.</given-names></name><name><surname>Graff</surname><given-names>J.R.</given-names></name></person-group><article-title>Targeting the eIF4F translation initiation complex for cancer therapy</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>2466</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.4161/cc.7.16.6464</pub-id><pub-id pub-id-type="pmid">18719377</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diab</surname><given-names>S.</given-names></name><name><surname>Teo</surname><given-names>T.</given-names></name><name><surname>Kumarasiri</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>F.</given-names></name><name><surname>Basnet</surname><given-names>S.K.</given-names></name><name><surname>Sykes</surname><given-names>M.J.</given-names></name><name><surname>Albrecht</surname><given-names>H.</given-names></name><name><surname>Milne</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation</article-title><source>ChemMedChem</source><year>2014</year><volume>9</volume><fpage>962</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201300552</pub-id><pub-id pub-id-type="pmid">24677692</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>M.</given-names></name><name><surname>Elia</surname><given-names>A.J.</given-names></name><name><surname>Chio</surname><given-names>II</given-names></name><name><surname>Hamada</surname><given-names>K.</given-names></name><name><surname>Fukunaga</surname><given-names>R.</given-names></name><name><surname>Mak</surname><given-names>T.W.</given-names></name></person-group><article-title>Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year><volume>107</volume><fpage>13984</fpage><lpage>13990</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008136107</pub-id><pub-id pub-id-type="pmid">20679220</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>E.</given-names></name><name><surname>Jenni</surname><given-names>S.</given-names></name><name><surname>Kabha</surname><given-names>E.</given-names></name><name><surname>Takrouri</surname><given-names>K.J.</given-names></name><name><surname>Yi</surname><given-names>T.</given-names></name><name><surname>Salvi</surname><given-names>N.</given-names></name><name><surname>Luna</surname><given-names>R.E.</given-names></name><name><surname>Gavathiotis</surname><given-names>E.</given-names></name><name><surname>Mahalingam</surname><given-names>P.</given-names></name><name><surname>Arthanari</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2014</year><volume>111</volume><fpage>E3187</fpage><lpage>E3195</lpage><pub-id pub-id-type="doi">10.1073/pnas.1410250111</pub-id><pub-id pub-id-type="pmid">25049413</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yue</surname><given-names>P.</given-names></name><name><surname>Khuri</surname><given-names>F.R.</given-names></name><name><surname>Sun</surname><given-names>S.Y.</given-names></name></person-group><article-title>The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation</article-title><source>Neoplasia</source><year>2010</year><volume>12</volume><fpage>346</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1593/neo.10144</pub-id><pub-id pub-id-type="pmid">20360945</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Aktas</surname><given-names>B.H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Sahoo</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Denoyelle</surname><given-names>S.</given-names></name><name><surname>Kabha</surname><given-names>E.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Freedman</surname><given-names>R.Y.</given-names></name><etal/></person-group><article-title>Tumor suppression by small molecule inhibitors of translation initiation</article-title><source>Oncotarget</source><year>2012</year><volume>3</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">22935625</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descamps</surname><given-names>G.</given-names></name><name><surname>Gomez-Bougie</surname><given-names>P.</given-names></name><name><surname>Tamburini</surname><given-names>J.</given-names></name><name><surname>Green</surname><given-names>A.</given-names></name><name><surname>Bouscary</surname><given-names>D.</given-names></name><name><surname>Maiga</surname><given-names>S.</given-names></name><name><surname>Moreau</surname><given-names>P.</given-names></name><name><surname>Gouill</surname><given-names>S.</given-names></name><name><surname>Pellat-Deceunynck</surname><given-names>C.</given-names></name><name><surname>Amiot</surname><given-names>M.</given-names></name></person-group><article-title>The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction</article-title><source>Br. J. Cancer</source><year>2012</year><volume>106</volume><fpage>1660</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.139</pub-id><pub-id pub-id-type="pmid">22510748</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attar-Schneider</surname><given-names>O.</given-names></name><name><surname>Drucker</surname><given-names>L.</given-names></name><name><surname>Zismanov</surname><given-names>V.</given-names></name><name><surname>Tartakover-Matalon</surname><given-names>S.</given-names></name><name><surname>Lishner</surname><given-names>M.</given-names></name></person-group><article-title>Targeting eIF4GI translation initiation factor affords an attractive therapeutic strategy in multiple myeloma</article-title><source>Cell. Signal.</source><year>2014</year><volume>26</volume><fpage>1878</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2014.05.005</pub-id><pub-id pub-id-type="pmid">24815186</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>T.</given-names></name><name><surname>Kabha</surname><given-names>E.</given-names></name><name><surname>Papadopoulos</surname><given-names>E.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name></person-group><article-title>4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>6028</fpage><lpage>6037</lpage><pub-id pub-id-type="pmid">25115391</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalingam</surname><given-names>P.</given-names></name><name><surname>Takrouri</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Sahoo</surname><given-names>R.</given-names></name><name><surname>Papadopoulos</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name><name><surname>Aktas</surname><given-names>B.H.</given-names></name><name><surname>Halperin</surname><given-names>J.A.</given-names></name><name><surname>Chorev</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their <italic>in&#x000a0;vitro</italic> characterization as inhibitors of protein-protein interaction</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><fpage>5094</fpage><lpage>5111</lpage><pub-id pub-id-type="doi">10.1021/jm401733v</pub-id><pub-id pub-id-type="pmid">24827861</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takrouri</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Papadopoulos</surname><given-names>E.</given-names></name><name><surname>Sahoo</surname><given-names>R.</given-names></name><name><surname>Kabha</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Cantel</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name><name><surname>Halperin</surname><given-names>J.A.</given-names></name><name><surname>Aktas</surname><given-names>B.H.</given-names></name><name><surname>Chorev</surname><given-names>M.</given-names></name></person-group><article-title>Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2014</year><volume>77</volume><fpage>361</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.03.034</pub-id><pub-id pub-id-type="pmid">24675136</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yefidoff-Freedman</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Sahoo</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name><name><surname>Halperin</surname><given-names>J.A.</given-names></name><name><surname>Aktas</surname><given-names>B.H.</given-names></name><name><surname>Chorev</surname><given-names>M.</given-names></name></person-group><article-title>3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction</article-title><source>Chembiochem</source><year>2014</year><volume>15</volume><fpage>595</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300723</pub-id><pub-id pub-id-type="pmid">24458973</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukhele</surname><given-names>S.</given-names></name><name><surname>Bah</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Forman-Kay</surname><given-names>J.D.</given-names></name></person-group><article-title>Interaction of the eukaryotic initiation factor 4E with 4E-BP2 at a dynamic bipartite interface</article-title><source>Structure</source><year>2013</year><volume>21</volume><fpage>2186</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.08.030</pub-id><pub-id pub-id-type="pmid">24207126</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igreja</surname><given-names>C.</given-names></name><name><surname>Peter</surname><given-names>D.</given-names></name><name><surname>Weiler</surname><given-names>C.</given-names></name><name><surname>Izaurralde</surname><given-names>E.</given-names></name></person-group><article-title>4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4790</fpage><pub-id pub-id-type="doi">10.1038/ncomms5790</pub-id><pub-id pub-id-type="pmid">25179781</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>D.</given-names></name><name><surname>Igreja</surname><given-names>C.</given-names></name><name><surname>Weber</surname><given-names>R.</given-names></name><name><surname>Wohlbold</surname><given-names>L.</given-names></name><name><surname>Weiler</surname><given-names>C.</given-names></name><name><surname>Ebertsch</surname><given-names>L.</given-names></name><name><surname>Weichenrieder</surname><given-names>O.</given-names></name><name><surname>Izaurralde</surname><given-names>E.</given-names></name></person-group><article-title>Molecular architecture of 4E-BP translational inhibitors bound to eIF4E</article-title><source>Mol. Cell</source><year>2015</year><volume>57</volume><fpage>1074</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.01.017</pub-id><pub-id pub-id-type="pmid">25702871</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bah</surname><given-names>A.</given-names></name><name><surname>Vernon</surname><given-names>R.M.</given-names></name><name><surname>Siddiqui</surname><given-names>Z.</given-names></name><name><surname>Krzeminski</surname><given-names>M.</given-names></name><name><surname>Muhandiram</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Kay</surname><given-names>L.E.</given-names></name><name><surname>Forman-Kay</surname><given-names>J.D.</given-names></name></person-group><article-title>Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch</article-title><source>Nature</source><year>2015</year><volume>519</volume><fpage>106</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature13999</pub-id><pub-id pub-id-type="pmid">25533957</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Polunovsky</surname><given-names>V.</given-names></name><name><surname>Bitterman</surname><given-names>P.B.</given-names></name><name><surname>Wagner</surname><given-names>C.R.</given-names></name></person-group><article-title>Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target</article-title><source>Med. Res. Rev.</source><year>2012</year><volume>32</volume><fpage>786</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1002/med.21260</pub-id><pub-id pub-id-type="pmid">22495651</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Jacobson</surname><given-names>B.</given-names></name><name><surname>McCauley</surname><given-names>J.</given-names></name><name><surname>Kratzke</surname><given-names>R.</given-names></name><name><surname>Bitterman</surname><given-names>P.B.</given-names></name><name><surname>Wagner</surname><given-names>C.R.</given-names></name></person-group><article-title>Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation</article-title><source>Mol. Pharm.</source><year>2013</year><volume>10</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1021/mp300699d</pub-id><pub-id pub-id-type="pmid">23289910</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>B.</given-names></name><name><surname>Benyumov</surname><given-names>A.O.</given-names></name><name><surname>Ghosh</surname><given-names>P.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Avdulov</surname><given-names>S.</given-names></name><name><surname>Dahlberg</surname><given-names>P.S.</given-names></name><name><surname>Peterson</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Polunovsky</surname><given-names>V.A.</given-names></name><name><surname>Bitterman</surname><given-names>P.B.</given-names></name><name><surname>Wagner</surname><given-names>C.R.</given-names></name></person-group><article-title>Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation</article-title><source>ACS Chem. Biol.</source><year>2009</year><volume>4</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1021/cb9000475</pub-id><pub-id pub-id-type="pmid">19351181</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>E.Z.</given-names></name><name><surname>Jacobson</surname><given-names>B.A.</given-names></name><name><surname>Patel</surname><given-names>M.R.</given-names></name><name><surname>Okon</surname><given-names>A.M.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Xiong</surname><given-names>K.</given-names></name><name><surname>Vaidya</surname><given-names>A.J.</given-names></name><name><surname>Bitterman</surname><given-names>P.B.</given-names></name><name><surname>Wagner</surname><given-names>C.R.</given-names></name><name><surname>Kratzke</surname><given-names>R.A.</given-names></name></person-group><article-title>Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells</article-title><source>Invest. New Drugs</source><year>2014</year><volume>32</volume><fpage>598</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1007/s10637-014-0076-7</pub-id><pub-id pub-id-type="pmid">24711125</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Kopecky</surname><given-names>D.J.</given-names></name><name><surname>Mihalic</surname><given-names>J.</given-names></name><name><surname>Jeffries</surname><given-names>S.</given-names></name><name><surname>Min</surname><given-names>X.</given-names></name><name><surname>Heath</surname><given-names>J.</given-names></name><name><surname>Deignan</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Guimaraes</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><fpage>3837</fpage><lpage>3851</lpage><pub-id pub-id-type="doi">10.1021/jm300037x</pub-id><pub-id pub-id-type="pmid">22458568</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>J.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name></person-group><article-title>Targeting the eIF4A RNA helicase as an anti-neoplastic approach</article-title><source>Biochim. Biophys. Acta</source><year>2014</year><fpage>781</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">25234619</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusyk</surname><given-names>A.</given-names></name><name><surname>Almendro</surname><given-names>V.</given-names></name><name><surname>Polyak</surname><given-names>K.</given-names></name></person-group><article-title>Intra-tumour heterogeneity: a looking glass for cancer?</article-title><source>Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/nrc3261</pub-id><pub-id pub-id-type="pmid">22513401</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polyak</surname><given-names>K.</given-names></name></person-group><article-title>Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nm.3518</pub-id><pub-id pub-id-type="pmid">24710378</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onsum</surname><given-names>M.D.</given-names></name><name><surname>Geretti</surname><given-names>E.</given-names></name><name><surname>Paragas</surname><given-names>V.</given-names></name><name><surname>Kudla</surname><given-names>A.J.</given-names></name><name><surname>Moulis</surname><given-names>S.P.</given-names></name><name><surname>Luus</surname><given-names>L.</given-names></name><name><surname>Wickham</surname><given-names>T.J.</given-names></name><name><surname>McDonagh</surname><given-names>C.F.</given-names></name><name><surname>Macbeath</surname><given-names>G.</given-names></name><name><surname>Hendriks</surname><given-names>B.S.</given-names></name></person-group><article-title>Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients</article-title><source>Am. J. Pathol.</source><year>2013</year><volume>183</volume><fpage>1446</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.07.015</pub-id><pub-id pub-id-type="pmid">24035511</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>C.</given-names></name><name><surname>Shetty</surname><given-names>J.</given-names></name><name><surname>Prasad</surname><given-names>K.H.</given-names></name></person-group><article-title>Immunohistochemical profile and morphology in triple - negative breast cancers</article-title><source>J. Clin. Diagn. Res.</source><year>2013</year><volume>7</volume><fpage>1361</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">23998066</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>A.C.</given-names></name><name><surname>Hammond</surname><given-names>M.E.</given-names></name><name><surname>Schwartz</surname><given-names>J.N.</given-names></name><name><surname>Hagerty</surname><given-names>K.L.</given-names></name><name><surname>Allred</surname><given-names>D.C.</given-names></name><name><surname>Cote</surname><given-names>R.J.</given-names></name><name><surname>Dowsett</surname><given-names>M.</given-names></name><name><surname>Fitzgibbons</surname><given-names>P.L.</given-names></name><name><surname>Hanna</surname><given-names>W.M.</given-names></name><name><surname>Langer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>118</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.2775</pub-id><pub-id pub-id-type="pmid">17159189</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widakowich</surname><given-names>C.</given-names></name><name><surname>de Castro</surname><given-names>G.</given-names></name><name><surname>de Azambuja</surname><given-names>E.</given-names></name><name><surname>Dinh</surname><given-names>P.</given-names></name><name><surname>Awada</surname><given-names>A.</given-names></name></person-group><article-title>Review: side effects of approved molecular targeted therapies in solid cancers</article-title><source>Oncologist</source><year>2007</year><volume>12</volume><fpage>1443</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.12-12-1443</pub-id><pub-id pub-id-type="pmid">18165622</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J.</given-names></name><name><surname>Ascierto</surname><given-names>P.A.</given-names></name><name><surname>Dreno</surname><given-names>B.</given-names></name><name><surname>Atkinson</surname><given-names>V.</given-names></name><name><surname>Liszkay</surname><given-names>G.</given-names></name><name><surname>Maio</surname><given-names>M.</given-names></name><name><surname>Mandala</surname><given-names>M.</given-names></name><name><surname>Demidov</surname><given-names>L.</given-names></name><name><surname>Stroyakovskiy</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1408868</pub-id><pub-id pub-id-type="pmid">25265494</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramon</surname><given-names>Y.C.S.</given-names></name><name><surname>De Mattos-Arruda</surname><given-names>L.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Peg</surname><given-names>V.</given-names></name></person-group><article-title>The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets</article-title><source>Clin. Transl. Oncol.</source><year>2014</year><volume>16</volume><fpage>937</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1007/s12094-014-1203-9</pub-id><pub-id pub-id-type="pmid">25060567</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussemart</surname><given-names>L.</given-names></name><name><surname>Malka-Mahieu</surname><given-names>H.</given-names></name><name><surname>Girault</surname><given-names>I.</given-names></name><name><surname>Allard</surname><given-names>D.</given-names></name><name><surname>Hemmingsson</surname><given-names>O.</given-names></name><name><surname>Tomasic</surname><given-names>G.</given-names></name><name><surname>Thomas</surname><given-names>M.</given-names></name><name><surname>Basmadjian</surname><given-names>C.</given-names></name><name><surname>Ribeiro</surname><given-names>N.</given-names></name><name><surname>Thuaud</surname><given-names>F.</given-names></name><etal/></person-group><article-title>eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies</article-title><source>Nature</source><year>2014</year><volume>513</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature13572</pub-id><pub-id pub-id-type="pmid">25079330</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkogkas</surname><given-names>C.G.</given-names></name><name><surname>Khoutorsky</surname><given-names>A.</given-names></name><name><surname>Ran</surname><given-names>I.</given-names></name><name><surname>Rampakakis</surname><given-names>E.</given-names></name><name><surname>Nevarko</surname><given-names>T.</given-names></name><name><surname>Weatherill</surname><given-names>D.B.</given-names></name><name><surname>Vasuta</surname><given-names>C.</given-names></name><name><surname>Yee</surname><given-names>S.</given-names></name><name><surname>Truitt</surname><given-names>M.</given-names></name><name><surname>Dallaire</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Autism-related deficits via dysregulated eIF4E-dependent translational control</article-title><source>Nature</source><year>2013</year><volume>493</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/nature11628</pub-id><pub-id pub-id-type="pmid">23172145</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkogkas</surname><given-names>C.G.</given-names></name><name><surname>Khoutorsky</surname><given-names>A.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Jafarnejad</surname><given-names>S.M.</given-names></name><name><surname>Prager-Khoutorsky</surname><given-names>M.</given-names></name><name><surname>Giannakas</surname><given-names>N.</given-names></name><name><surname>Kaminari</surname><given-names>A.</given-names></name><name><surname>Fragkouli</surname><given-names>A.</given-names></name><name><surname>Nader</surname><given-names>K.</given-names></name><name><surname>Price</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes</article-title><source>Cell Rep.</source><year>2014</year><volume>9</volume><fpage>1742</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.064</pub-id><pub-id pub-id-type="pmid">25466251</pub-id></element-citation></ref></ref-list></back></article>